Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Siefker-Radtke AO, Cho DC, Diab A, Sznol M, et al. Eur Urol 2022;82:365-373.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Siefker-Radtke AO, Cho DC, Diab A, Sznol M, et al. Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. Eur Urol 2022;82:365-373.
PMID: 35643589